Tejaswini Kulkarni

Tejaswini Kulkarni
Associate Professor

Associate Scientist (C), Center for Clinical and Translational Science (CCTS) , General Clinical Research Center
Associate Professor (P), Medicine - Pulmonary, Allergy, & Critical Care Medicine , Department of Medicine

Overview

Dr. Kulkarni received her medical training and internship at Bangalore Medical College and Research Institute following which she obtained a Masters in Public Health at Harvard T.H. Chan School of Public Health. She completed a residency in Internal Medicine at Wayne State University 2013. Dr. Kulkarni then completed a clinical and research fellowship in the Division of Pulmonary, Allergy and Critical Care medicine at UAB in 2016 and was appointed as faculty within this Division.

Dr. Kulkarni currently serves as the Director of Interstitial Lung Disease Program at UAB and champions efforts to provide quality clinical care to patients with interstitial lung diseases at her center. As a member of the steering committee of ILD network at American College of Chest Physicians, she strives to promote education for early diagnosis and quality treatment of these patients within the community as well. Dr. Kulkarni is currently principal/co-investigator on clinical trials studying new therapeutics for ILD and her research focuses on developing imaging biomarkers to prognosticate and assess response to therapy among these patients.

Selected Publications

Academic Article

Year	Title	Altmetric
2022	Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respiratory Research. 23. 2022
2022	Editorial: Fibrotic Lung Disease—“Lumping” the Progressive Phenotype. Frontiers in Medicine. 9. 2022
2021	Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations. PLoS One. 16. 2021
2021	Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry. Respiratory Medicine. 189. 2021
2021	In this Issue. Journal of Palliative Medicine. 24:1419-1419. 2021
2021	Top Ten Tips Palliative Care Clinicians Should Know about Prognostication in Oncology, Dementia, Frailty, and Pulmonary Diseases. Journal of Palliative Medicine. 24:1391-1397. 2021
2021	Citrullinated vimentin mediates development and progression of lung fibrosis. Science Translational Medicine. 13. 2021
2020	Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial 2020
2020	Monocyte-derived alveolar macrophage apolipoprotein E participates in pulmonary fibrosis resolution. JCI Insight. 5. 2020
2020	The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosis. Respiratory Medicine. 161. 2020
2019	Acute exacerbation of idiopathic pulmonary fibrosis: who to treat, how to treat. 2019
2019	Preoperative Evaluation of Patients With Interstitial Lung Disease. Chest. 156:826-833. 2019
2019	Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients. PLoS One. 14. 2019
2019	Update in pulmonary fibrosis 2018. American Journal of Respiratory and Critical Care Medicine. 200:292-300. 2019
2019	Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine. 200:199-208. 2019
2019	Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis 2019
2017	Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis. Journal of Immunology. 199:1596-1605. 2017
2016	Alveolar epithelial disintegrity in pulmonary fibrosis 2016
2016	A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival 2016
2016	A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival. Respiratory Medicine. 115:33-38. 2016
2016	Matrix remodeling in pulmonary fibrosis and emphysema. American Journal of Respiratory Cell and Molecular Biology. 54:751-760. 2016
2016	Flexible bronchoscopy is safe and effective in adult subjects supported with extracorporeal membrane oxygenation 2016
2016	Oxidative modifications of protein tyrosyl residues are increased in plasma of human subjects with interstitial lung disease. American Journal of Respiratory and Critical Care Medicine. 193:861-866. 2016
2016	Attenuated heme oxygenase-1 responses predispose the elderly to pulmonary nontuberculous mycobacterial infections 2016
2016	Extracorporeal membrane oxygenation in adults: A practical guide for internists. Cleveland Clinic Journal of Medicine. 83:373-384. 2016
2015	Heme oxygenase-1-mediated autophagy protects against pulmonary endothelial cell death and development of emphysema in cadmium-treated mice 2015
2015	Heme oxygenase-1 protects Corexit 9500ainduced respiratory epithelial injury across species. PLoS One. 10. 2015
2014	Characteristics of patients with pulmonary venoocclusive disease awaiting transplantation. Annals of the American Thoracic Society. 11:1411-1418. 2014
2013	Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide. American Journal of Respiratory and Critical Care Medicine. 188:1407-1412. 2013

Research Overview

As a clinician-scientist in the Pulmonary, Allergy and Critical Care Division at UAB, Dr. Kulkarni's area of excellence is in clinical and translational research in the field of idiopathic pulmonary fibrosis and other interstitial lung diseases. Her research is focused on developing imaging based as well as molecular biomarkers to prognosticate and assess response to therapy in patients with pulmonary fibrosis. She is currently principal investigator and co-investigator on clinical trials studying new therapeutics in interstitial lung diseases. She also serves as co-investigator of NIH studies focusing on translational investigations into the pathogenesis of idiopathic pulmonary fibrosis within the Division.